[1] SATSANGI J, SILVERBERG MS, VERMEIRE S, et al.The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications[J]. Gut, 2006, 55(6): 749-753.
[2] LIU AL, LYU H, QIAN JM.Management of acute severe ulcerative colitis[J]. Chinese Journal of Gastroenterology(胃肠病学), 2019, 24(6): 321-325.
[3] WANG LB, TANG SQ.Progress in the treatment of ulcerative colitis with biological agents[J]. Chinese Journal of Postgraduates of Medicine(中国医师进修杂志), 2020, 43(12): 1141-1144.
[4] FEUERSTEIN JD, ISAACS KL, SCHNEIDER Y, et al.AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis[J]. Gastroenterology, 2020, 158(5): 1450-1461.
[5] DA SILVA BC, LYRA AC, ROCHA R, et al.Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis[J]. World J Gastroenterol, 2014, 20(28): 9458-9467.
[6] Inflammatory bowel disease group, Chinese society of gastroen-terology, Chinese medical association. Chinese consensus diagnosis and treatment of inflammatory bowel disease(Beijing, 2018)[J]. Chinese Journal of Digestion(中华消化杂志), 2018, 38(5): 292-311.
[7] DASSOPOULOS T, COHEN RD, SCHERL EJ, et al.Ulcerative colitis care pathway[J]. Gastroenterology, 2015, 149(1): 238-245.
[8] RUBIN DT, ANANTHAKRISHNAN AN, SIEGEL CA, et al.ACG clinical guideline: ulcerative colitis in adults[J]. Am J Gastroenterol, 2019, 114(3): 384-413.
[9] UNGARO R, MEHANDRU S, ALLEN PB, et al.Ulcerative colitis[J]. Lancet, 2017, 389(10080): 1756-1770.
[10] TIMMER A, PATTON PH, CHANDE N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis[J]. Cochrane Database Syst Rev, 2016, 2016(5): CD000478.
[11] PUGLIESE D, FELICE C, PAPA A, et al.Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future[J]. Expert Rev Clin Immunol, 2017, 13(3): 223-233.
[12] ARGOLLO M, KOTZE PG, KAKKADASAM P, et al.Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(11): 702-710.
[13] LI K, TONG YL, YU XF.Nutritional support for inflammatory bowel disease[J]. International Journal of Digestive Diseases(国际消化病杂志), 2015, 35(3): 171-173, 221.
[14] GLICK LR, CIFU AS, FELD L.Ulcerative colitis in adults[J]. JAMA, 2020, 324(12): 1205-1206.
[15] LICHTENSTEIN L, RON Y, KIVITY S, et al.Infliximab-related infusion reactions: systematic review[J]. J Crohns Colitis, 2015, 9(9): 806-815.
[16] LUTHRA P, PEYRIN-BIROULET L, FORD AC.Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2015, 41(12): 1227-1236.
[17] FEAGAN BG, RUTGEERTS P, SANDS BE, et al.Vedolizumab as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2013, 369(8): 699-710.
[18] NOVAK G, HINDRYCKX P, KHANNA R, et al.The safety of vedolizumab for the treatment of ulcerative colitis[J]. Expert Opin Drug Saf, 2017, 16(4): 501-507.
[19] COLOMBEL JF, SANDS BE, RUTGEERTS P, et al.The safety of vedolizumab for ulcerative colitis and Crohn's disease[J]. Gut, 2017, 66(5): 839-851.
[20] LOFTUS EV JR, COLOMBEL JF, FEAGAN BG, et al.Long-term efficacy of vedolizumab for ulcerative colitis[J]. J Crohns Colitis, 2017, 11(4): 400-411.
[21] SANDS BE, PEYRIN-BIROULET L, LOFTUS EV JR, et al.Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis[J]. N Engl J Med, 2019, 381(13):1215-1226.
[22] TAKATSU N, HISABE T, HIGASHI D, et al.Vedolizumab in the treatment of ulcerative colitis: an evidence-based review of safety, efficacy, and place of therapy[J]. Core Evid, 2020, 15: 7-20.
[23] MCLEAN LP, CROSS RK.Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis published correction appears in Expert Opin Drug Metab Toxicol[J]. Expert Opin Drug Metab Toxicol, 2016, 12(7): 833-842. |